Seastar Medical Holding Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The company is a pre-revenue medical technology developer focused on its Selective Cytopheretic Device (SCD), initially for acute kidney injury and other acute organ-injury indications. Financial amounts below are in U.S. dollars; amounts reported in thousands are converted to millions where indicated.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 or comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.697 million | $1.730 million |
| General and administrative expense | $2.253 million | $2.851 million |
| Total operating expenses / operating loss | $3.950 million | $4.581 million |
| Net loss | $12.697 million | $7.096 million |
| Net loss per share, basic and diluted | $0.19 | $0.54 |
| Cash used in operating activities | $3.488 million | $2.294 million |
| Cash provided by financing activities | $8.331 million | $2.972 million |
| Cash at period-end | $5.019 million | $0.176 million at December 31, 2023 |
Margins are not meaningful because the company reported no revenue. The net loss increase primarily reflects non-cash fair-value and financing-related losses: a $5.758 million loss on convertible notes and a $2.846 million loss on liability-classified warrants, partly offset by lower operating expenses and interest expense. No income tax provision was recorded.
At March 31, 2024, total liabilities were $12.213 million, including $2.922 million of notes payable (current and long-term) and $1.135 million of current convertible notes at fair value. Total assets were $7.740 million and stockholders’ deficit was $4.473 million. The company paid off its LMFA and LMFAO notes during the quarter; its remaining Maxim note is due in 2025, and insurance financing is due in 2024.
Material changes and financing
- Operating expenses fell 14% year over year. R&D was nearly flat; lower external-service costs and patent fees were largely offset by increased clinical-trial and personnel spending. G&A declined 21%, including lower professional, marketing, insurance and other costs.
- Q1 financing included a registered direct offering and concurrent warrant placement that generated approximately $9.0 million gross proceeds. The company also received proceeds from warrant exercises and new convertible notes.
- Approximately $3.3 million face value of Investor D debt was converted into approximately $9.5 million of common stock. Common shares outstanding increased from 47.6 million at year-end to 75.4 million at March 31; additional warrants and potential conversions could cause further dilution.
- The company terminated its Tumim equity line in February 2024. It stated it had no committed external source of funds and did not expect near-term cash proceeds from warrant exercises.
Outlook, risks, and unusual items
- Going concern: Management says cash is insufficient to fund operations, clinical-trial costs and capital needs for at least 12 months from issuance of the financial statements. The filing states that substantial doubt exists about the company’s ability to continue as a going concern. Additional financing may not be available on acceptable terms, or at all.
- Product and regulatory outlook: The pediatric SCD received FDA Humanitarian Device Exemption approval in February 2024, and management expects near-term commercialization. The adult SCD remains in development, with FDA approval and commercialization dependent on further clinical and regulatory progress. No quantified revenue or earnings guidance is provided.
- Additional support: In April 2024, an NIH grant of $3.6 million was awarded to a consortium for a clinical trial involving adult SCD in acute decompensated heart failure; SeaStar expects to receive a portion, but the filing does not specify its amount.
- Redemption and dilution risk: Investor D received rights, after a suspension period, to require redemption of outstanding convertible notes at 200% of the conversion amount. A subsequent April 2024 side letter extended certain suspended rights through May 30, 2024.
- Internal controls: Management concluded disclosure controls were ineffective as of March 31, 2024 because of material weaknesses in financial reporting controls. Remediation efforts are underway but are not yet considered complete.
- Filing-status item: The cover page marks “No” for whether all required Exchange Act reports had been filed during the preceding 12 months; the filing provides no explanation in the supplied text.
- The company cites early-stage medical-device risks, including clinical and regulatory uncertainty, product acceptance, financing needs, intellectual-property protection and product liability. It reported no legal proceeding believed likely to have a material adverse effect and no new risk factors beyond those in its 2023 Form 10-K.
Most important facts for investors to verify
- Available cash, subsequent financing, operating cash burn and the company’s ability to fund at least 12 months of operations.
- Timing and commercial prospects for the pediatric SCD, and clinical and regulatory milestones for adult SCD programs.
- Investor D conversion, redemption and default provisions, as well as the amount and timing of any remaining obligations.
- Potential dilution from outstanding warrants, convertible securities and future capital raises.
- Progress in remediating material weaknesses and the reason the cover page indicates required-report filing status was “No.”
- The amount and timing of SeaStar’s expected share of the NIH-funded trial and any conditions attached to that funding.